Wed, Oct 22, 2014, 9:50 AM EDT - U.S. Markets close in 6 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

  • fraud_z_buster fraud_z_buster May 22, 2012 10:38 AM Flag

    Who is Thomas DeZao, TLON's new Commercialization chief.

    To understand who Mr. Tom DeZao is, look no further past Mr. Howard Pien, who was recently appointed to TLON's BOD.

    See, Mr. Pien served as President, Chief Executive, and Chairman of the Board of Chiron Corporation from 2003 until 2006 (when Chiron was acquired by Novartis), where Mr. DeZao worked with with "Howie" Pien. The final result for Mr Howard Pien and Mr Thomas DeZao and the Chiron team was, making Chiron attractive enough for acquisition by Novartis

    Here we go again, this dynamic duo spells only one thing, TLON may get a favorable PDUFA review, on or before August 12, 2012, and engineering TLON's Marqibo commercialization process to be attractive enough for acquisition. The big ball is now rolling, imo.

    TLON's President and CEO hinted on Mr DeZao's hire, "With Marqibo(R)'s PDUFA date of August 12, 2012, active partnership discussions, and ongoing Phase 3 trials in adult acute lymphoblastic leukemia (ALL) and adult non-Hodgkin's lymphoma (NHL), Talon will greatly benefit from the addition of Tom's commercial, business development, and strategy experience,"

    Today's PR is the biggest and brighest hint, and the loudest annoucement of the outcome of the August 12, 2012 PDUFA date. I think TLON may get provisional approval with a narrow label for the use of Marqibo. Broad label may come at the conclusion of the Phase 3 trial, imo

    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.